Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast ...

Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing ...

The rates of life-threatening breast cancer are spiking among women of all ages, with a significant increase in those under ...

Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral ...

Cancer researchers at Fox Chase Cancer Center in Philadelphia see promise in personalized medicine to help crack the code on ...

Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel, targeted, small molecule cancer ...

Thirty years after the sequencing of the BRCA1 cancer-associated gene, access to genetic tests and awareness about its risks ...

They are also finding genetic links to pancreatic cancer that could help detect it sooner and lead to new treatment options.

BRCA mutations are inextricably linked with breasts, but they can also lead to cancer in the pancreas, the prostate, and maybe more parts of the body.